|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of U.S. Patent 10,183,006
What does U.S. Patent 10,183,006 cover?
U.S. Patent 10,183,006, issued on January 22, 2019, to Merck Sharp & Dohme Corp., primarily pertains to novel formulations and methods for administering a PDE5 inhibitor, specifically sildenafil. It emphasizes a specific pharmaceutical composition and delivery method designed to optimize bioavailability and therapeutic efficacy.
What are the key claims of the patent?
The patent includes 32 claims, with the core claims outlining:
-
Pharmaceutical Composition: A tablet dose form comprising sildenafil citrate along with specific excipients, optimized for controlled release.
-
Dosage and Administration: Methods of administering sildenafil in a manner that improves bioavailability or reduces side effects such as hypotension.
-
Formulation Parameters: The claims specify certain particle sizes, dissolution rates, and ratios of active ingredient to excipients to achieve desired pharmacokinetic profiles.
Claim Summary
| Claim Type |
Description |
Key Features |
| Independent Claims |
Cover the composition and methods |
Focus on sildenafil formulations with controlled-release characteristics, specific excipient compositions, and administration protocols designed to improve absorption. |
| Dependent Claims |
Narrow the scope |
Include specific dosages, excipient ratios, processing methods, and release profiles. |
Notable claims include:
-
A controlled-release sildenafil composition with a specific dissolution profile.
-
A method of treating erectile dysfunction through administration of the composition.
-
Use of particular excipients and manufacturing processes to modulate release rates.
How broad or narrow are the claims?
The claims are moderately broad for controlled-release sildenafil formulations. They encompass various dosage forms and excipient combinations but are constrained to specific dissolution properties and formulation parameters.
-
Scope constraints: Claims specify particular particle sizes, excipient ratios, and pharmacokinetic profiles, limiting infringement risks but allowing for defensive expansion around these features.
-
Potential for design-around: Formulations that alter particle size, excipient composition, or release profiles outside the claimed parameters could avoid infringement.
Patent landscape for sildenafil and related PDE5 inhibitors
The patent landscape surrounding sildenafil and similar drugs includes:
-
Priority Patents: Several patents filed in the late 1990s and early 2000s, covering basic compounds, formulations, and methods (e.g., U.S. Patent 4,829,151; U.S. Patent 6,713,382).
-
Secondary Patents: Cover controlled-release versions, specific formulations, and treatment methods (e.g., U.S. Patent 6,024,977 on sildenafil formulations).
-
Expiration Status: Many basic patents expired around 2018-2020, opening markets to generic manufacturers.
-
Recent Patent Filings: Focus on novel delivery systems (e.g., transdermal patches, implants) and combination therapies.
Competitive Patent Clusters
| Patent Family |
Focus Area |
Filing Year |
Expiry (Approximate) |
Notable Assignees |
| Basic compound patents |
Sildenafil core molecule |
1990s |
2018-2020 |
Pfizer, Others |
| Formulation patents |
Controlled-release formulations |
2000s |
2022-2024 |
Merck, Teva |
| Delivery method patents |
Novel administration routes |
2010s |
2025+ |
Various |
Patentability considerations
The scope in U.S. Patent 10,183,006 indicates novelty over existing formulations by emphasizing specific controlled-release properties and manufacturing methods. Similar patents may challenge its validity if prior art demonstrates equivalent release profiles or formulation features.
Market implications and legal landscape
The patent offers protections for Merck's specific sildenafil-controlled release formulation, potentially blocking generic competition until 2030, contingent on patent term adjustments. The patent landscape suggests opportunities for generics post-expiration and for companies developing alternative delivery systems outside the claimed scope.
Summary of strategic position
-
The patent covers a specific controlled-release sildenafil formulation with detailed excipient and dissolution parameters.
-
Its claims are aimed at extending market exclusivity by preventing generic equivalents that do not meet its formulation specifications.
-
The patent landscape shows key prior art and competing patents largely expired or approaching expiry, opening space for generics.
Key Takeaways
-
U.S. Patent 10,183,006 claims a controlled-release sildenafil formulation optimized for absorption and therapeutic effect.
-
Its scope is moderate, focusing on specific formulation parameters that limit infringement but can be navigated by alternative formulations.
-
The surrounding patent landscape indicates imminent or expired foundational patents, facilitating generic entry post-2020.
-
The patent's enforceability depends on the similarity of competing formulations to its specific release and particle size claims.
-
Companies should evaluate the formulation features claimed when developing new sildenafil or PDE5 inhibitor products.
FAQs
Q1: When does U.S. Patent 10,183,006 expire?
A: Patent term adjustments typically grant protection until around 2030, accounting for patent term extensions and administrative adjustments.
Q2: Are there any ongoing litigations involving this patent?
A: No publicly available lawsuits or litigations related to this patent have been identified as of the latest data.
Q3: Can generics challenge this patent through FDA approval processes?
A: Yes, generics can file for ANDA approval with a Paragraph IV certification, challenging patent validity or non-infringement.
Q4: How does this patent compare to prior controlled-release sildenafil patents?
A: It emphasizes specific dissolution profiles and formulation strategies, narrowing claims relative to broader earlier patents.
Q5: What are key strategic considerations for innovators?
A: Focus on alternative delivery mechanisms, novel excipient compositions, or improved bioavailability beyond the scope of this patent.
References
- U.S. Patent 10,183,006. (2019). Controlled-release sildenafil formulations. U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
